ESR1 and breast carcinoma: Tamoxifen (Tx), an estrogen receptor alpha (ER-ɑ) antagonist, is recommended as adjuvant therapy in breast cancer (BC) patients with an ER-ɑ expressing, lymph-node-negative or lymph-node-positive tumor [16,17].